LiY,YangT,WeiS,WangJ,WangM., 2013.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer,PLoSOne 8 e52093 -
LeeJK,KimTM,KohY,LeeSH,KimDW,JeonYK, 2012.Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation,Lung Cancer 77 460 -3
SasakiT,KoivunenJ,OginoA,YanagitaM,NikiforowS,ZhengW, 2011.A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors,Cancer Res 71 6051 -60
ChenX,ZhangJ,HuQ,LiX,ZhouC., 2013.A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4- ALK fusion gene,Lung Cancer 81 308 -10
MiyanagaA,ShimizuK,NoroR,SeikeM,KitamuraK,KosaihiraS, 2013.Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation,BMC Cancer 13 262 -
TiseoM,GelsominoF,BoggianiD,BortesiB,BartolottiM,Bozzetti, 2011.EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations,Lung Cancer 71 241 -3
ChiariR,DurantiS,LudoviniV,BellezzaG,PiredduA,MinottiV, 2014.Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene,J Clin Oncol 32 e30 -2
YYang,XSong,JZhu,XZhou, 2014.A rare case of adenocarcinoma of the lung harboring EGFR, BRAF, and ALK activating mutations,Chest 146 640A -
ZhouJ,ZhengJ,ZhaoJ,ShengY,DingW,ZhouJ, 2015.Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutationand anaplastic lymphoma kinase rearrangement,Thorac Cancer 6 216 -9